immune-system modulator for myasthenia gravis MG

University of Illinois-Chicago scientist receives $530,480 to test immune system modulator for myasthenia gravis

posted on March 14, 2011 - 3:51pm

Update (June 10, 2013): In 2013, Matthew Meriggioli relocated from the University of Illinois to the Novartis Institutes for BioMedical Research in Cambridge, Mass. The laboratory work on GM-CSF has been completed, and Meriggioli and other investigators are looking at the possibility of starting the clinical trial at an alternative site.